Authors
Latest:
Dr. Annunziata on Efforts to Prevent Gynecologic CancersChristina M. Annunziata, MD, PhD, investigator, Women's Malignancies Branch, head, Translational Genomics Section, National Cancer Institute, discusses the importance on efforts being done to prevent gynecologic cancers.
Latest:
PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Whom to Treat?PARP inhibitors have emerged as agents that generate improved oncological outcomes in select patient populations with metastatic castration-resistant prostate cancer.
Latest:
Dr. Tan on the Risk of Novel Coronavirus for Patients With CancerChristina Tan, MD, MPH, discusses the potential impact of the novel coronavirus on patients with cancer.
Latest:
Future Directions in ALK-Positive and BRAF-Positive NSCLC ManagementPanelists discuss how advancements in targeted therapies and personalized medicine are crucial for addressing the pressing unanswered questions in the management of ALK-positive and BRAF-positive cancers.
Latest:
Survivorship Starts at Diagnosis in Breast CancerThe inclusion of patients from the time of diagnosis and encompassing family, friends, and caregivers is central to moving survivorship care forward, especially for breast cancer survivorship, which has high survival rates for early disease and the emergence of novel treatments for advanced cancers.
Latest:
Narsoplimab Trial ResultsThe panel of transplant experts discuss the results of the phase 2 trial of narsoplimab and the pending FDA approval of this agent for treatment of transplant-associated of thrombotic microangiopathy.
Latest:
Dr. Mariette on Takeaways from a Study of Esophageal and Gastric Cancer SurgeryChristophe Mariette, MD, PhD, surgical oncologist, professor of Surgery, University Hospital of Lille, discusses the main takeaways from a study investigating postoperative mortality after patients undergo surgery for esophageal and gastric cancer.
Latest:
Dr. Klebanoff on Biosimilars Reducing Financial Toxicity in Breast CancerChristopher A. Klebanoff, MD, discusses using biosimilars to reduce financial toxicity in breast cancer.
Latest:
Dr. Yasenchak on the Safety Profile of Brentuximab Vedotin/Nivolumab in Hodgkin LymphomaChristopher A. Yasenchak, MD, discusses the safety profile of brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) in patients with Hodgkin lymphoma.
Latest:
Should You Pursue a Surgical Oncology Fellowship?Christopher B. Allard, MD, shares his views on pursuing a surgical oncology fellowship.
Latest:
Dr. Crane on the Use of Proton Therapy and the MR-Linear Accelerator in GI MalignanciesChristopher Crane, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the emergence and success of new technologies in the treatment of patients with gastrointestinal (GI) malignancies.
Latest:
How to Survive With Limited Finances (and a Family) as a Hematology-Oncology FellowIf you are anything like me, despite working incredibly hard, not getting paid adequately for many years, and accumulating an incredible amount of debt, you could not imagine any other career.
Latest:
Dr. Barbieri on SPOP Mutations in Prostate CancerChristopher E. Barbieri, MD, PhD, surgeon, researcher in prostate cancer genomics, Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and New-York Presbyterian, discusses the implications of SPOP mutations in patients with prostate cancer.
Latest:
Dr. Dandoy on Overcoming Challenges with TA-TMAChristopher E. Dandoy, MD, MSc, shares advice for how to overcome the challenges in managing transplanted-associated thrombotic microangiopathy. The primary challenges are diagnosing and identifying TA-TMA in patients.
Latest:
Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic CancerAn integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.
Latest:
Dr. Heery on Advancements in Treatment of Neuroendocrine TumorsDr. Christopher Heery, medical oncologist, National Cancer Institute, discusses the progress that has been made in the treatment of patients with neuroendocrine tumors.
Latest:
Dr. Hoimes on EV-103 Results in Urothelial CancerChristopher J. Hoimes, DO, discusses the results of the EV-103 trial in patients with locally advanced or metastatic urothelial cancer.
Latest:
Dr. Kane on Challenges Facing Genetic Testing in Prostate CancerChristopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses challenges facing genetic testing for patients with prostate cancer.
Latest:
Dr. Logothetis Discusses Prostate Cancer TherapyDr. Christopher Logothetis, from the MD Anderson Cancer Center, Discusses Prostate Cancer Therapy
Latest:
Our Move to an EHRThe initial capital outlay for transitioning to an EHR is not small. In fact, cost is one of the main reasons practices have been slow to adopt EHRs.
Latest:
Dr. Pietras Discusses Pain Management in Ovarian CancerChristopher J. Pietras, MD, director, Palliative Care, assistant clinical professor, University of California, Los Angeles (UCLA) School of Medicine, discusses pain management in patients with ovarian cancer.
Latest:
Dr. Lieu Discusses the Focus of Future Research in mCRCChristopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses where future research should focus in metastatic colorectal cancer.
Latest:
Dr. Evans Discusses the Subgroup Analysis Results of the PREVAIL StudyChristopher P. Evans, MD, professor, chairman, Department of Urology, University of California at Davis School of Medicine, UC Davis Comprehensive Cancer Center, discusses the results of an analysis of patients with and without visceral disease defined as liver and/or lung metastases who participated in the PREVAIL study.
Latest:
New Imaging Strategies for Prostate Cancer ExploredContinuing research will have to evaluate whether combining serum biomarkers or other measurable clinical factors with multiparametric magnetic resonance imaging results can help make negative or inaccurate prostate biopsies a rarity rather than the norm.
Latest:
Dr. Pietras on Palliative Care for Patients With Ovarian CancerChristopher J. Pietras, MD, director, Palliative Care, assistant clinical professor, University of California, Los Angeles (UCLA) School of Medicine, discusses palliative care for patients with ovarian cancer.
Latest:
Dr. Shea on Dermatological Management in MelanomaChristopher R. Shea, MD, the Eugene J. Van Scott Professor of Medicine, chief of the Section of Dermatology at The University of Chicago Medicine, discusses the dermatological management of melanoma.
Latest:
Dr. Seet on Aspects of Treatment Discontinuation in CMLChristopher S. Seet, MD, PhD, hematologist and oncologist, UCLA, discusses aspects of treatment discontinuation in chronic myeloid leukemia (CML).
Latest:
Dr. Sweeney on the Phase III ENZAMET Trial in Metastatic Hormone-Sensitive Prostate CancerChristopher Sweeney, MBBS, medical oncologist at the Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, discusses results of the phase III ENZAMET trial, which looked at standard therapy with or without enzalutamide as a treatment for patients with metastatic hormone-sensitive prostate cancer.
